Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06476158

Safer Personalised Cancer Treatment Digital Follow-up

Led by Nordlandssykehuset HF · Updated on 2024-06-26

900

Participants Needed

1

Research Sites

186 weeks

Total Duration

On this page

Sponsors

N

Nordlandssykehuset HF

Lead Sponsor

U

University of Tromso

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to investigate patient harm/ adverse events, overall survival and health related quality of life under treatment with immunotherapy medication in cancer patients when they are followed up by a personalized digital program where the patients report symptoms directly to health care personnel. The main questions the clinical trial aims to answer are: * How often and how severe are immunotherapy related adverse events/ side effects when patients are followed up by a digital personalized patient-reporting system compared to standard follow-up? * How are life quality and survival affected for patients followed up by a digital personalized patient-reporting system compared to follow-up standard follow-up?? Participants under immunotherapy cancer treatment will be followed up by a digital patient reporting program in one group, and compared to a group of cancer patients receiving the same treatment, but with standard follow-up without a digital program in another group. Researchers will compare the two groups to see if there any differences in how many patients who develop immunotherapy related patient harm and how long the patients live.

CONDITIONS

Official Title

Safer Personalised Cancer Treatment Digital Follow-up

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Above 18 years of age
  • Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification
  • Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications.
Not Eligible

You will not qualify if you...

  • Hematological cancer
  • Gynecological cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Nordlandssykehuset HF

Bodø, Nordland, Norway, 8092

Actively Recruiting

Loading map...

Research Team

E

Ellinor C Haukland, MD, Phd

CONTACT

S

Siv Gyda Aanes, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safer Personalised Cancer Treatment Digital Follow-up | DecenTrialz